Prometheus Biosciences, Inc. Contracts & Agreements
29 Contracts & Agreements
- Business Finance (7 contracts)
- Business Operations (2)
- Human Resources (10)
- Intellectual Property (5)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (2)
- Agreement and Plan of Merger, dated as of April 15, 2023, by and among Prometheus Biosciences, Inc., Merck & Co., Inc., and Splash Merger Sub, Inc (Filed With SEC on April 17, 2023)
- Underwriting Agreement, dated December 8, 2022, by and among the Registrant and Goldman Sachs & Co. LLC, SVB Securities LLC and Jefferies LLC, as representatives of the several... (Filed With SEC on December 9, 2022)
- Description of Registered Securities (Filed With SEC on March 9, 2022)
- Amended & Restated Non-Employee Director Compensation Program (Filed With SEC on March 9, 2022)
- Annual Incentive Plan (Filed With SEC on March 9, 2022)
- First Amendment to Lease Agreement, by and between SNH Medical Office Properties Trust and the Registrant, dated October 29, 2021 (Filed With SEC on November 12, 2021)
- Amended and Restated Exclusive License Agreement, dated August 6, 2021, by and between Cedars-Sinai Medical Center and the Registrant (Filed With SEC on August 11, 2021)
- Form of Underwriting Agreement (Filed With SEC on March 8, 2021)
- Specimen stock certificate evidencing the shares of common stock (Filed With SEC on March 8, 2021)
- Prometheus Biosciences, Inc. 2021 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder (Filed With SEC on March 8, 2021)
- Prometheus Biosciences, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on March 8, 2021)
- Non-Employee Director Compensation Program (Filed With SEC on March 8, 2021)
- Employment Letter Agreement, dated February 7, 2021, by and between Mark Stenhouse and the Registrant (Filed With SEC on March 8, 2021)
- Amended and Restated Investors Rights Agreement, dated October 30, 2020, by and among the Registrant and certain of its stockholders (Filed With SEC on February 19, 2021)
- Warrant issued to Oxford Finance LLC, dated January 24, 2020 (Filed With SEC on February 19, 2021)
- Prometheus Biosciences, Inc. 2017 Equity Incentive Plan, as amended, including form of stock option agreement thereunder (Filed With SEC on February 19, 2021)
- Amended and Restated Employment Letter Agreement, dated February 17, 2021, by and between Mark C. McKenna and the Registrant (Filed With SEC on February 19, 2021)
- Amended and Restated Employment Letter Agreement, dated February 17, 2021, by and between Keith W. Marshall, Ph.D. and the Registrant (Filed With SEC on February 19, 2021)
- Amended and Restated Employment Letter Agreement, dated February 17, 2021, by and between Allison Luo, M.D. and the Registrant (Filed With SEC on February 19, 2021)
- Amended and Restated Employment Letter Agreement, dated February 17, 2021, by and between Timothy K. Andrews and the Registrant (Filed With SEC on February 19, 2021)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on February 19, 2021)
- Loan and Security Agreement, dated January 24, 2020, by and among Oxford Finance LLC, Prometheus Laboratories, Inc. and the Registrant, as amended (Filed With SEC on February 19, 2021)
- Sublease Agreement, dated December 31, 2020, by and between Prometheus Laboratories Inc. and the Registrant (Filed With SEC on February 19, 2021)
- Exclusive License Agreement, dated September 1, 2017, by and between Cedars-Sinai Medical Center and the Registrant, as amended (Filed With SEC on February 19, 2021)
- Exclusive License Agreement, dated March 22, 2019, by and between Cedars-Sinai Medical Center and the Registrant (Filed With SEC on February 19, 2021)
- Exclusive License Agreement, dated March 22, 2019, by and between Cedars-Sinai Medical Center and the Registrant (Filed With SEC on February 19, 2021)
- Companion Diagnostics Development and Collaboration Agreement, dated as of March 25, 2019, by and between Millennium Pharmaceuticals, Inc. and the Registrant (Filed With SEC on February 19, 2021)
- License Agreement, dated March 18, 2020, by and between Alloy Therapeutics, LLC and the Registrant (Filed With SEC on February 19, 2021)
- Co-development and Manufacturing Agreement, dated as of July 30, 2020, by and between Dr. Falk Pharma GmbH and the Registrant (Filed With SEC on February 19, 2021)
